The Panel now recommends against the use of tixagevimab plus cilgavimab for pre-exposure prophylaxis (PrEP) of COVID-19.
These sections summarize the data on antiviral agents, including remdesivir, ritonavir-boosted nirmatrelvir, and anti-SARS-CoV-2 monoclonal antibodies.
These sections summarize the data on IL-6 inhibitors, kinase inhibitors, and other immunomodulators.
This section discusses screening, prevention, and treatment for thromboembolism in people with COVID-19.
These sections summarize the data on metformin, colchicine, fluvoxamine, and other miscellaneous drugs.
These sections discuss the rationale for using supplements in people with COVID-19.
Review the data on using certain concomitant therapies in people with COVID-19.